CSL acquires option to Pevion's candidiasis vaccine

In the first deal for the product, CSL has acquired the right of first refusal to a licence to commercialise Pevion Biotech's therapeutic vaccine against Candida albicans, PEV7, in Australia and New Zealand.

The two companies have also entered into an agreement for the supply of certain components of Pevion's virosomal vaccines, although...